Crisaborole
EUCRISA
What it isTopical PDE4 inhibitor; mild to moderate atopic dermatitis.
Why this oneSteroid-sparing on the face and flexures with no atrophy risk.
What limits itApplication-site burning is common and limits adherence. Less effective than a mid-potency steroid.
FDA-approved for
- mild-to-moderate atopic dermatitis (2016)
FDA label
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Mild–moderate atopic dermatitis | Patients ≥3 months | Apply thin layer BID | BID; reduce to QD once clinical effect achieved | BID |
Renal Undefined
Hepatic Undefined
Instructions
- Apply a thin layer to affected areas twice daily
- Once clinical effect is achieved, consider reducing to once daily
- For topical use only; not for ophthalmic, oral, or intravaginal use
Cautions
- Hypersensitivity reactions including contact urticaria — discontinue immediately if they occur
Adverse reactions
- Application site pain (burning/stinging)
- Contact urticaria (<1%); allergic contact dermatitis (postmarketing)
Pregnancy Case-report data insufficient; no adverse developmental effects in animals at up to 2–3× MRHD
Lactation No human milk data; systemically absorbed; weigh benefit vs risk
NO BOXED WARNINGS
Principal riskApplication-site burning
Cost, est. cash$200–$1,500/month
Generic entry2030 est.
Classes and tags
Clinical profile
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityLocal irritation, sensitization or administration-site injury; negligible systemic toxicity at usual use.
Mechanism of action: Crisaborole ballicule
